NYU Langone Medical Center's tip sheet to the 44th annual meeti...(n and prognostication. Researchers f...),Health

Researchers from NYU Langone Medical Center and Rosetta Genomics Ltd. present evidence from a study that used microRNAs (mirs) to discover potentially novel biomarkers for mesothelioma. Mirs are non-coding RNAs that suppress translation of genes into proteins and have a central role in gene regulation in health and disease. To better understand the molecular events that lead to the development of mesothelioma, the researchers examined whether mir profiles differed significantly between mesothelioma and normal abdominal mesothelium. Of 136 mirs that were expressed in at least one set of peritoneum (abdominal cavity) samples, 66 showed significant differential expression: 34 were upregulated in tumor samples, while 32 were downregulated in normal tissue. Validation of this data in larger subsets is ongoing.

Abstract # 5065
Androgen receptor (AR) overexpression and sensitivity to hormones reversed by epigenetic therapy that restores Pura to a transcriptional repressor complex (RC) of AR deregulated in hormone refractory prostate cancer (HRPC).
NYU Cancer Institutes Anna Ferrari, M.D., associate professor of medicine; co-program leader for the genitourinary cancer research program, at NYU Langone Medical Center

NYU Langone Medical Center researchers present a new strategy that may lead to new therapies for prostate cancers that are resistant to anti-androgen therapy. These cancers are especially difficult to treat because they have limited responsiveness to chemotherapy and account for 35% of men with a diagnosis of prostate cancer, and eventually all men on hormone therapy for recurrent disease. The prognosis is less favorable than for cancers that are responding to androgen suppression therapy, one of the mainstays of prostate cancer treatment. The researchers reversed the resistance of prostate cancer cells
'/>"/>